News - OxyDial Inc

Mar 12 2025

Novo Nordisk’s Rare Disease Unit Expects Breakthrough in Sickle Cell Treatment

Novo Nordisk is advancing etavopivat for sickle cell disease, aiming to reduce vaso-occlusive crises (VOCs) by 50% in a Phase 3 trial next year. The drug came from Novo’s $1.1 …

OxyDial

Mar 5 2025

AstraZeneca’s $160M Deal Aims to Elevate Anemia Treatment for Patients in China

Roxadustat, a breakthrough anemia treatment, is set for further expansion in China as AstraZeneca acquires full rights from FibroGen in a $160 million deal. Originally developed to treat anemia from …

OxyDial

Feb 26 2025

Advancing Treatment Options: Pyrukynd’s Potential in Thalassemia and Sickle Cell Disease

Agios Pharmaceuticals continues its commitment to expanding the use of Pyrukynd (mitapivat) for patients with thalassemia and sickle cell disease, two conditions with significant unmet medical needs. In recent Phase …

OxyDial

Feb 19 2025

New Pediatric Breakthrough: Mitapivat Shows Efficacy in Treating PK Deficiency in Children

A recent Phase 3 trial (ACTIVATE-Kids) by Agios Pharmaceuticals demonstrated that mitapivat, an oral pyruvate kinase (PK) activator, significantly improved hemoglobin levels in children with PK deficiency who are not …

OxyDial

Feb 13 2025

New Combination Therapy by Astra Zeneca Shows Promise in Reducing Anemia in PNH Patients

A recent clinical trial published in Blood highlights a breakthrough in treating paroxysmal nocturnal hemoglobinuria (PNH). This rare, life-threatening blood disorder leads to the destruction of red blood cells. The …

OxyDial

Feb 7 2025

Emmaus Secures Market Exclusivity for Endari in Saudi Arabia

Emmaus Life Sciences has been granted market exclusivity for its sickle cell treatment, Endari® (L-glutamine oral powder), in the Kingdom of Saudi Arabia (KSA). The exclusivity, awarded by NUPCO, the …

OxyDial

Jan 31 2025

Novo Nordisk Expands Sickle Cell Pipeline with IMMvention’s Novel BACH1 Inhibitor Deal

In a strategic move to strengthen its position in the sickle cell disease market, Novo Nordisk has partnered with IMMvention Therapeutix, Inc. to co-develop innovative oral treatments. This collaboration focuses …

OxyDial

Jan 23 2025

Bristol Myers Squibb, Texas Children’s Global HOPE, and Baylor College of Medicine, Launch Program to Address Sickle Cell Disease in Sub-Saharan Africa

The Bristol Myers Squibb Foundation, Texas Children’s Global Health Network HOPE, and Baylor College of Medicine Global Health have announced a new initiative to combat sickle cell disease in Sub-Saharan …

OxyDial

Jan 17 2025

Agios Secures EC Endorsement for Sickle Cell Therapy

Agios Pharmaceuticals has announced that the European Commission (EC) has granted orphan medicinal product designation to their oral therapy, mitapivat, for treating sickle cell disease (SCD). Already recognized with orphan …